FDA Guidance Priorities For FY 2022 Include Transitioning EUAs; List Includes CDS Software Again

The US agency’s device center on 26 October published its A and B lists of guidance documents it will prioritize in fiscal year 2022, including drafting guidances to transition emergency use authorized products to full marketing status, and finalizing a clinical decision support software guidance that’s been four years in the making.